

Docket No. 295889US0X PCT



10591604 - GAT-1649  
**MAIL STOP PCT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Masao DAIMON, et al.

SERIAL NO: 10/591,604

GAU:

FILED: September 5, 2006

EXAMINER:

FOR: DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618


Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423



10591604 - GAU: 1649

SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 295889US0X PCT		SERIAL NO. 10/591,604	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Masao DAIMON, et al.			
				FILING DATE September 5, 2006		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
/R.H./	AJ	01 66133	09/13/2001	WO (with English abstract and equivalent of US 2003 0036512)		NO	
↓	AK	00 62797	10/26/2000	WO (with English abstract) only		NO	
	AL	2001 235470	08/31/2001	JP no English translation		NO	
	AM						
	AN						
	AO						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
/R.H./	AP	HENRY C. MCGILL et al., "RELATION OF GLYCOHEMOGLOBIN AND ADIPOSITY TO ATHEROSCLEROSIS IN YOUTH", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, Vol. 15, No. 4, pages 431-440, 1995					
↓	AQ	GERALD M. REAVEN, "ROLE OF INSULIN RESISTANCE IN HUMAN DISEASE", DIABETES, Vol. 37, No. 12, pages 1595-1607, 1988.					
	AR	MEIR J. STAMPFER et al., "A PROSPECTIVE STUDY OF PLASMA HOMOCYST(E)INE AND RISK OF MYOCARDIAL INFARCTION IN US PHYSICIANS, JAMA, Vol. 268, No. 7, pages 877-881, 1992.					
	AS	JOSEPH L. WITZTUM et al., "ROLE OF OXIDIZED LOW DENSITY LIPOPROTEIN IN ATHEROGENESIS", THE JOURNAL OF CLINICAL INVESTIGATION, Vol. 88, No. 6, pages 1785-1792, 1991.					
	AT	D. WOOD, "EUROPEAN AND AMERICAN RECOMMENDATIONS FOR CORONARY HEART DISEASE PREVENTION", EUROPEAN HEART JOURNAL, Vol. 19, pages A12-A19, 1998.					
	AU	MICHAEL J. DONOVAN et al., "BRAIN DERIVED NEUROTROPHIC FACTOR IS AN ENDOTHELIAL CELL SURVIVAL FACTOR REQUIRED FOR INTRAMYOCARDIAL VESSEL STABILIZATION", DEVELOPMENT, Vol. 127, pages 4531-4550, 2000.					
	AV	TAKESHI NAKAHASHI et al., "VASCULAR ENDOTHELIAL CELLS SYNTHESIZE AND SECRETE BRAIN-DERIVED NEUROTROPHIC FACTOR", FEBS LETTERS, Vol. 470, No. 2, pages 113-117, 2000.					
	AW	JUKKA O. HILTUNEN et al., "NERVE GROWTH FACTOR AND BRAIN-DERIVED NEUROTROPHIC FACTOR MRNAS ARE REGULATED IN DISTINCT CELL POPULATIONS OF RAT HEART AFTER ISCHAEMIA AND REPERFUSION", JOURNAL OF PATHOLOGY, Vol. 194, pages 247-253, 2001.					
	AX	G. N. CHALDAKOV et al., " NGF, BDNF, LEPTIN, AND MAST CELLS IN HUMAN CORONARY ATHEROSCLEROSIS AND METABOLIC SYNDROME", ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, Vol. 109, No. 4, pages 357- 360, 2001					
↓	AY	SHAHRAM S. GHOLAMI et al., "THE EFFECT OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ADENO-ASSOCIATED VIRUS MEDIATED BRAIN DERIVED NEUROTROPHIC FACTOR ON NEUROGENIC AND VASCULOGENIC ERECTILE DYSFUNCTION INDUCED BY HYPERLIPIDEMIA", THE JOURNAL OF UROLOGY, Vol. 169, pages 1577-1581, 2003.					
	AZ	/Robert Hayes/				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered 12/06/2010		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



U.S. PCT Application Serial No: 10/591,604  
Filed: September 5, 2006  
Masao DAIMON, et al.  
Docket No. 295889 US

### STATEMENT OF RELEVANCY

- 1) References AJ-AL have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References            have been cited in the corresponding            Search Report. A copy of these references is being submitted herewith.
- 3) References AP-AY are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References            are additional prior art known to Applicant. A copy of these references is being submitted herewith.